News

Patients' Worry, Not Risk, Drives Double Mastectomies

View on the News

We Need to Educate Our Patients

The findings suggest that "we, as physicians, may not be adequately educating our patients about the risk for recurrent disease," said Dr. Jyoti D. Patel, who moderated the press conference.

In general, women with localized breast cancer in one breast have less than a 1% chance of developing a new cancer in the unaffected breast and an 8% chance of recurrence in the affected breast or a nearby lymph node. The risk for developing a new cancer in the contralateral breast rises to approximately 10%-15% if the patient has a history of breast or ovarian cancer in two or more primary relatives, with a similar or slightly greater increased risk from a positive genetic mutation, Dr. Patel estimated. Having both clinical risk factors confers a 10- to 20-fold increase in risk.

Dr. Jyoti Patel
Unfortunately, many women overestimate their risk of developing breast cancer in the contralateral breast and undergo unnecessary surgery, she commented. This study suggests that physicians re-examine how they communicate with their patients regarding the decision to undergo prophylactic mastectomy.

"Many women fear recurrence, and they also fear surveillance. They worry about, if they’re 35 years old, what a lifetime of screening for the contralateral breast might look like if they end up getting multiple biopsies. So how we put that in perspective for our young population will become vitally important," Dr. Patel said.

Dr. Patel, a thoracic oncologist at Northwestern University in Chicago, is a member of ASCO’s Cancer Communications Committee.


 

FROM A PRESS CONFERENCE SPONSORED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

"Many women fear recurrence, and they also fear surveillance. They worry about, if they’re 35 years old, what a lifetime of screening for the contralateral breast might look like if they end up getting multiple biopsies. So how we put that in perspective for our young population will become vitally important," said Dr. Patell, a thoracic oncologist at Northwestern University in Chicago and a member of ASCO’s Cancer Communications Committee.

Dr. Hawley reported having no financial disclosures.

Pages

Recommended Reading

FDA Approves Ultrasound Screening of Dense Breasts
MDedge Internal Medicine
One Year of Trastuzumab Remains the Standard in Early Breast Cancer
MDedge Internal Medicine
EMILIA Confirms T-DM1 Overall Survival Advantage
MDedge Internal Medicine
Another Study Finds No Glargine, Breast Cancer Link
MDedge Internal Medicine
The Cancer Screening Wars
MDedge Internal Medicine
Screening Cuts Breast Cancer Deaths by 20%
MDedge Internal Medicine
Older Women Lived Longer With Radiotherapy After Lumpectomy
MDedge Internal Medicine
ASCO Update Keeps Breast Cancer Survivor Guidelines Intact
MDedge Internal Medicine
Breast Cancer Mortality Higher in Blacks Than Whites
MDedge Internal Medicine
Screening Mammograms Overdiagnosed More Than 1 Million Women
MDedge Internal Medicine